STML - Stemline Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
11.60
+0.05 (+0.43%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close11.55
Open11.55
Bid7.50 x 1000
Ask12.15 x 800
Day's Range11.24 - 11.63
52 Week Range7.82 - 20.55
Volume370,905
Avg. Volume682,150
Market Cap455.437M
Beta (3Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire25 days ago

    Stemline Therapeutics Announces Validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA)

    Stemline Therapeutics, Inc. (STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that the European Medicines Agency (EMA) has completed its validation of the Marketing Authorization Application (MAA) for ELZONRIS™ (tagraxofusp-erzs). Stemline submitted the MAA earlier this month seeking approval of ELZONRIS for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Under European Union legislation, a medicinal product of major public health interest may be reviewed under an accelerated assessment procedure.

  • GlobeNewswirelast month

    Consolidated Research: 2019 Summary Expectations for Marriott International, Calavo Growers, Kinsale Capital Group, Fluidigm, Goldman Sachs BDC, and Stemline Therapeutics — Fundamental Analysis, Key Performance Indications

    NEW YORK, Jan. 24, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswirelast month

    Stemline Therapeutics Closes $92 Million Public Offering of Common Stock

    Stemline Therapeutics, Inc. (STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced the closing of a previously announced underwritten public offering of 10,222,222 shares of its common stock, which included the exercise in full of the option to purchase 1,333,333 additional shares, at a price of $9.00 per share. J.P. Morgan Securities LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. Cantor Fitzgerald & Co., Ladenburg Thalmann & Co. Inc. and H.C. Wainwright & Co., LLC acted as co-lead managers and Roth Capital Partners, LLC, ThinkEquity, a division of Fordham Financial Management, Inc., A.G.P./Alliance Global Partners, National Securities Corporation, and Aegis Capital Corp. acted as co-managers for the offering.

  • GlobeNewswirelast month

    Stemline Therapeutics Announces Upsizing and Pricing of $80 Million Public Offering of Common Stock

    Stemline Therapeutics, Inc. (STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced the pricing of an underwritten public offering of 8,888,889 shares of its common stock at a price of $9.00 per share, with expected gross proceeds to Stemline of $80 million. Stemline has also granted the underwriters a 30-day option to purchase up to 1,333,333 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. Cantor Fitzgerald & Co., Ladenburg Thalmann & Co. Inc. and H.C. Wainwright & Co., LLC are acting as co-lead managers and Roth Capital Partners, LLC, ThinkEquity, a division of Fordham Financial Management, Inc., A.G.P./Alliance Global Partners, National Securities Corporation, and Aegis Capital Corp. are acting as co-managers for the offering.

  • GlobeNewswirelast month

    Stemline Therapeutics Announces Proposed Public Offering of Common Stock

    Stemline Therapeutics, Inc. (STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced that it intends to offer and sell, subject to market conditions, 6,600,000 shares of its common stock in an underwritten public offering. In addition, Stemline intends to grant the underwriters a 30-day option to purchase up to an additional 990,000 shares of its common stock offered in the public offering. J.P. Morgan Securities LLC is acting as book-running manager for the offering.

  • GlobeNewswire2 months ago

    Stemline Therapeutics Announces Submission of European Marketing Authorization Application (MAA) for ELZONRIS™

    Stemline Therapeutics, Inc. (STML), a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that it has submitted the marketing authorization application (MAA) for ELZONRIS (tagraxofusp) to the European Medicines Agency (EMA). The MAA seeks approval for treating patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). In November 2018, the EMA granted the ELZONRIS MAA accelerated assessment.

  • GlobeNewswire2 months ago

    Stemline Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

    Stemline Therapeutics, Inc. (STML), a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that Ivan Bergstein, M.D., Stemline’s CEO, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 5:00 PM PT at the Westin St. Francis Hotel in San Francisco, CA. ELZONRIS (tagraxofusp), a CD123-directed cytotoxin, was approved by the Food and Drug Administration (FDA) on December 21, 2018 for the treatment of adult and pediatric patients, two years and older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). In November 2018, the European Medicines Agency (EMA) granted ELZONRIS accelerated assessment to the upcoming marketing authorization application (MAA), which is expected to be submitted in the first quarter of 2019.

  • FDA Approves ELZONRIS™ (tagraxofusp), the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted Therapy
    PR Newswire2 months ago

    FDA Approves ELZONRIS™ (tagraxofusp), the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted Therapy

    - ELZONRIS is approved to treat adult and pediatric patients with both treatment-naïve and previously-treated BPDCN - Conference call scheduled for Friday, December 21, 2018 at 4:30 PM ET: Toll Free: (888) ...

  • ACCESSWIRE2 months ago

    These 4 Biotech Stocks Are Raising Eyebrows

    CORAL GABLES, FL / ACCESSWIRE / December 21, 2018 / The biotech industry is based on a framework made up of cunning edge medical technologies designed with the patient's best interests at heart. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Proteostasis Therapeutics, Inc (PTI), Alta Mesa Resources, Inc (AMR), and Stemline Therapeutics, Inc (STML) are 4 biotech stocks worth taking a look at. Premier Health Group (OTC:PHGRF) (CSE:PHGI), as a company, recognizes the importance of meeting the demands and needs of its 100,000, and growing, active patient network.

  • GlobeNewswire3 months ago

    Stemline Therapeutics Recaps Key Clinical Data Presentations from the American Society of Hematology (ASH) Annual Meeting

    NEW YORK, Dec. 06, 2018 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology.

  • GlobeNewswire3 months ago

    Stemline Therapeutics Highlights Four ELZONRIS Presentations, Including an Oral Presentation, at the Upcoming ASH Meeting

    NEW YORK, Nov. 30, 2018 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and commercialization of novel oncology.

  • GlobeNewswire3 months ago

    Report: Developing Opportunities within Koppers, Flowers Foods, Stemline Therapeutics, Aqua Metals, athenahealth, and Bojangles' — Future Expectations, Projections Moving into 2018

    NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire5 months ago

    Newman Ferrara LLP Announces Corporate Governance Investigation of Stemline Therapeutics Inc. - STML

    Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Stemline Therapeutics Inc. (“Stemline” or the “Company”) (STML) into potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”). Stemline, headquartered in New York, NY, is a clinical-stage biopharmaceutical company focused on the development and commercialization of oncology therapies. Newman Ferrara’s investigation focuses on decisions made by the Board, without shareholder approval, the result of which significantly diminish shareholder value and do not benefit the Company.